Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05581030 | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | PHASE1 | RECRUITING | 7 | — | — | May 1, 2023 | Oct 1, 2026 | Mar 6, 2026 | 1 | United States |
Mortality rate is hypothesized to be less than 10% when combining calaspargase pegol with Hyper-CVAD.
| Arm | Type | Description |
|---|---|---|
| Hyper-CVAD + Calaspargase pegol Treatment | EXPERIMENTAL | Participants will receive calaspargase pegol administered over 1 hour with each cycle of Hyper-CVAD, mini-CVD, and late intensification, beginning with Cycle 1B. Responding patients will have dose reduction of HyperCVAD for Cycles 2B-4B. Participants with CD20+ ALL will also be given Rituximab once per cycle. |
| Name | Type | Description |
|---|---|---|
| Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy) | DRUG | Hyper-CVAD consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term "hyper" refers to the hyperfractionated nature of the chemotherapy, which is given in small doses, more frequently, to minimize side effects. CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone. Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7. Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide. Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier. Course B: Methotrexate Day 1 and Cytarabine Days 2 and 3. Dosage is individualized to the patient. |
| Calaspargase Pegol | DRUG | Calaspargase pegol 2000 IU/m\^2 (capped at 3750 IU) will be administered beginning in cycle 1B of Hyper-CVAD, and will continue at this dose for the duration of the trial. |
| Rituximab | DRUG | Rituximab 375mg/m\^2 will be administered once per cycle for patients with CD20+ ALL. |
Inclusion Criteria: * Pathologically confirmed Philadelphia negative B- or T-cell acute lymphoblastic leukemia, with \>10% peripheral blood or bone marrow lymphoblasts at diagnosis. * Treatment and full recovery from arm 1A of the Hyper-CVAD regimen. * Be willing and able to provide written informe...